

CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON

Tech ID: 23254 / UC Case 2013-136-0

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	11,873,319	01/16/2024	2013-136

BRIEF DESCRIPTION

Interferons have potential in the treatment of a large number of human cancers since these molecules can directly inhibit the proliferation of human tumor cells. The anti-proliferative activity is also synergistic with a variety of approved chemotherapeutic agents such as cisplatin, 5FU and paclitaxel. Secondly, the immunomodulatory activity of interferon proteins can lead to the induction of an anti-tumor immune response. In addition, interferons play a role in cross-presentation of antigens in the immune system.

UC Berkeley researchers have created methods and compositions that can be used for increasing the production of a type I interferon (IFN) in a cell by increasing the level of a 2'-5' phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell.

SUGGESTED USES

» cancer therapeutic

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ BALB STING Knockout Mice
- ▶ Gasdermin-D Deficient Mice
- ▶ NLRC4 Knockout Mice

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.



INVENTORS

» Vance, Russell E.

OTHER INFORMATION

CATEGORIZED AS

- » Medical
- » Disease: Cancer
- » Therapeutics

RELATED CASES

2013-136-0